On March 8, 2022 Fulgent Genetics, Inc. (NASDAQ: FLGT) ("Fulgent Genetics" or the "company") , a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, reported that members of its management team are scheduled to virtually participate in Oppenheimer’s 32nd Annual Healthcare Conference on Tuesday, March 15, 2022 (Press release, Fulgent Pharma, MAR 8, 2022, View Source [SID1234609696]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

These representatives of the company will conduct a presentation beginning at approximately 9:20 a.m. Eastern Time (6:20 a.m. Pacific Time).

A live webcast of the session will be available on the Investor Relations section of the Fulgent Genetics website at ir.fulgentgenetics.com. A replay of the webcast will be accessible at ir.fulgentgenetics.com beginning approximately one hour following the completion of the event.